The antiviral and antiproliferative responses mediated by type I interferons (IFNs) depend on JAK/STAT signaling and ISGF3 (STAT1:STAT2: IRF9)-dependent transcription. In addition, type I IFNs stimulate STAT3 activation in many cell types, an event generally associated with cell cycle progression, survival, and proliferation. To gather more insight into this functionally contradictive phenomenon, we studied the regulation of STAT3 transcriptional activity upon type I IFN treatment. We show that IFN␣2 stimulation strongly induces STAT3 phosphorylation, nuclear translocation, and promoter binding, yet the activation of transcription of a STAT3-dependent reporter and endogenous genes, such as SOCS3 and c-FOS, is impaired. Simultaneous treatment with IFN␣2 and trichostatin A, as well as combined HDAC1/HDAC2 silencing, restores STAT3-dependent reporter gene and endogenous gene expression, strongly suggesting that HDAC1 and HDAC2 are directly involved in repressing IFN␣2-activated STAT3. Of note, single silencing of only one of the two HDACs does not lead to enhanced STAT3 activity, supporting a functional redundancy between these two enzymes. In sharp contrast, HDAC1 and HDAC2 activities are required for ISGF3-dependent gene expression. We conclude that HDAC1 and HDAC2 differentially modulate STAT activity in response to IFN␣2: while they are required for the induction of ISGF3-responsive genes, they impair the transcription of STAT3-dependent genes.-Icardi, L., Lievens, S., Mori, R., Piessevaux, J., De Cauwer, L., De Bosscher, K., Tavernier, J. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB J.
The type I interferon (IFN) family consists of a set of related cytokines, the IFN␣s, IFN␤s, and IFNs, that are widely studied for their antiviral (1), antiproliferative, and immunomodulatory properties (2) . IFNs elicit these activities through the activation of the IFN␣ receptor (IFN〈R) complex, composed of the IFN〈R1 and IFN〈R2 chains. Both receptor subunits are devoid of any enzymatic activity but are associated with the Janus kinases (JAKs), TYK2 and JAK1, respectively. The prototypical targets of these tyrosine kinases are members of the signal transducers and activators of transcription (STATs) family, and activation of STAT1 and STAT2 has been studied in great molecular detail. Upon phosphorylation, STAT1 associates with STAT2 and IRF9, leading to the formation of the interferonstimulated gene factor 3 (ISGF3) complex. ISGF3 acts as transcription factor and binds to the interferonstimulated responsive element (ISRE), promoting the transcription of the interferon-stimulated genes (ISGs) (3) . Additional studies have revealed that type I IFNs can activate all seven STAT family members, leading to the formation of different homodimers and heterodimers, as well as complexes with other transcription factors. These different patterns of STAT activation allow type I IFNs to orchestrate complex and specific biological responses in diverse cell types and under different physiological or pathological conditions (4) .
Of particular interest are the mechanisms controlling the activity of STAT3, since its persistent activation has been observed in a high number of human cancers (5) . As reviewed by van Boxel-Dezaire et al. (4) , IFN␣ stimulation was reported to trigger STAT3 activation in various cell types. In response to cytokine stimulation, STAT3 becomes rapidly phosphorylated at Tyr705 by the JAKs. This phosphorylation is required for STAT3 dimerization, nuclear translocation, DNA binding, and transcriptional activity (6) . In addition, phosphorylation of a single serine residue (Ser727) in the transcriptional activation domain is required for maximal transcriptional activation (7) . Recent studies showed that, in addition to phosphorylation, inducible lysine acetylation also has a central role in promoting the transcriptional activity of STAT3 (8 -9) . Of note, different lysines of STAT3 have been reported to be acetylated, and different patterns of acetylation have a different effect on its transcriptional activity. STAT3 acetylation is efficiently reverted by the histone deacetylases HDAC1, HDAC2, and HDAC3 (9 -11) , which directly associate with STAT3 and contribute to its negative regulation. Activated STAT3 stimulates the transcription of several genes involved in cell cycle progression, such as c-MYC, PIM1, and CYCLIN D1, and also up-regulates antiapoptotic genes such as BCL-2 and BCL-X (12) . In addition, for its ability to transform normal fibroblast cells and cause tumors in nude mice, STAT3 has been classified as an oncogene (13) . These effects are in sharp contrast with the proapoptotic and antiproliferative effects triggered by IFNs, which provide the rationale for their use in cancer therapy. To achieve a more detailed insight into the regulation of STAT3 in the IFN␣ signaling pathway, we investigate here its transcriptional activity, downstream of its activation by phosphorylation.
We report that, upon IFN␣2 treatment, the transcriptional activity of STAT3 is impaired, although its phosphorylation, nuclear translocation, and promoter binding are strongly induced and comparable to a positive control [leukemia-induced factor (LIF) treatment]. Interestingly, we find that the activities of HDAC1 and HDAC2, but not HDAC3, are directly involved in the negative regulation of STAT3 transcriptional activity. Indeed, interfering with HDAC1 and HDAC2 enzymatic functions, through trichostatin A treatment or combined siRNA-mediated silencing, restores the activation of both a STAT3-dependent reporter gene and STAT3-driven endogenous gene transcription. Of particular interest, recent observations showed that the activity of HDAC1 is crucial for the IFN-stimulated innate antiviral immunity, which relies on the activation of ISGF3-regulated genes (14) . In line herewith, our results show that interfering with the function of both HDAC1 and HDAC2 impairs the activation of ISGF3-regulated genes and simultaneously relieves a "frozen" pretranscriptional state of STAT3. In summary, our study indicates that HDAC1 and HDAC2 play a key role in the modulation of the IFN␣ response, exerting opposing regulation on ISGF3-and STAT3-dependent signaling. In addition, it unveils a hitherto unknown late-stage mechanism to suppress STAT3 transcriptional activity.
MATERIALS AND METHODS

Plasmids, cytokines, and drug treatments
The generation of the pXP2d2-rPAP1-luciferase reporter, originating from the rat pancreatitis-associated protein 1 (rPAP1) promoter was described previously (15) . The plasmid pCAGGS-HA-STAT3Y705F (dominant negative) was a gift from Dr. Toshio Hirano (Laboratory of Developmental Immunology, Osaka University, Osaka, Japan). The plasmid pMET7-Etag-hSTAT3 was constructed using the primer pair 5Ј-GCGGCGGCCGCAGCCCAATGGAATCAGCTACAG-3Ј and 5Ј-CGCCTCGAGTCACATGGGGGAGGTAGCGCA-3Ј to clone STAT3 into the pMET7 vector. The generation of Flp-In T-Rex HEK293 cells stably expressing the pXP2d2-rPAP1-luciferase reporter is described elsewhere (16) . Recombinant human IFN␣2 (PBL Interferon Source, Piscataway, NJ, USA) and recombinant human LIF (Millipore, Billerica, MA, USA) were used at 10 ng/ml unless specified otherwise. Trichostatin A (Sigma Aldrich, St. Louis, MO, USA) was used at 100 ng/ml and was added to the cell medium together with the cytokine stimulation.
Plasmid transfection protocols and luciferase assay
For plasmid transfection experiments, HEK293T cells were transfected overnight with 1 g of plasmid pCAGGS-HA-STAT3Y705F, using a standard calcium phosphate precipitation procedure (17) . The pMet7 empty vector construct was used to normalize for the amount of transfected DNA. For the acetylation assay, HEK293T cells were plated in 10-cm Petri dishes and transfected overnight with 5 g of plasmid pMET7-Etag-hSTAT3. For the luciferase assays, cells were transfected with the luciferase reporter vectors with the molar ratio (1:5) of reporter vector to expression vector. The next day, cells were washed with PBS, trypsinized, transferred to a 96-well plate, and left untreated or stimulated with the indicated amount of IFN␣2 or LIF for 24 h. Luciferase activity from triplicate samples was measured by chemiluminescence with a TopCount luminometer (Canberra-Packard, Waverley, UK) and expressed as fold induction (stimulated/nonstimulated).
Lysate preparation, Western blot analysis, and immunoprecipitation
At 48 h after transfection, cells were cultured for 4 h without FCS, stimulated, and lysed with 200 l of modified RIPA lysis buffer (200 mM NaCl; 50 mM Tris-HCl, pH 8; 0.05% SDS; 2 mM EDTA; 1% Nonidet P-40; 0.5% sodium deoxycholate; 1 mM Na 3 VO 4 ; 1 mM NaF; and Complete Protease Inhibitor Cocktail; Roche Applied Science, Penzberg, Germany). For the acetylation assay, cells were transfected with EtaghSTAT3, cultured 4 h without FCS, stimulated, and lysed with 1 ml of modified RIPA lysis buffer plus 1 M trichostatin A (TSA). Lysates were incubated with an anti-acetyl lysine antibody (Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C. Immune complexes were precipitated by adding 30 l of protein A-Sepharose beads (50% slurry) and rotated for 2 h at 4°C. Beads were washed 3 times with modified RIPA buffer, incubated with 10 l of 5ϫ SDS loading buffer, and boiled at 98°C for 10 min. Lysates were loaded on a 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (Amersham, Dubendorf, Switzerland). The following antibodies were used: rabbit polyclonal antibodies against endogenous STAT3 and phosphorylated Y 705 STAT3 and mouse monoclonal antibodies against HDAC1, HDAC2, HDAC3, and LAMIN A/C were purchased from Cell Signaling Technology; expression levels of HAtagged STAT3Y705F plasmid were revealed using an anti-HAtag monoclonal antibody from Boehringer Mannheim (Mannheim, Germany); anti-ACTIN mouse monoclonal antibody was purchased from Sigma Aldrich; mouse monoclonal antibody against GAPDH was purchased from Abcam (Cambridge, UK); either goat anti-mouse Dylight 800 or anti-rabbit Dylight 680 (Pierce, Rockford, IL, USA) was used as secondary Ab. Targeted proteins on the blots were visualized using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Nuclear extract preparation and STAT3-DNA binding assay
Nuclear extracts were prepared as described previously (18) , yet slightly modified. In brief, cells were washed with PBS and resuspended in 400 l ice-cold hypotonic buffer (10 mM Tris-HCl, pH 7.8; 5 mM MgCl 2 ; 10 mM KCl; 0.1 mM EDTA; 300 mM sucrose; 5 mM ␤-glycerophosphate; 0.5 mM DTT; and Complete Protease Inhibitor Cocktail). The cell suspension was briefly vortexed and allowed to swell for 15 min. Cells were then lysed by adding a final concentration of 0.5% Nonidet P-40, vortexing and incubating 10 min on ice. Afterward, nuclei were precipitated (1 min at 2000 rpm), and supernatant was removed. Isolated nuclei were washed 3 times in hypotonic buffer (after each wash, precipitated at 2000 rpm for 1 min). The nuclear pellet was lysed in 50 l hypertonic buffer (20 mM Tris-Cl, pH 7.8, 5 mM MgCl 2 ; 320 mM KCl; 0.2 mM EDTA; 25% glycerol; 0.5 mM DTT; 5 mM ␤-glycerophosphate; and Complete Protease Inhibitor Cocktail) and was incubated on ice for 30 min. Nuclear debris was removed through centrifugation at 13,000 rpm for 10 min. For the STAT3-DNA binding assay, the TransAM STAT3 kit (Active Motif, Carlsbad, CA, USA) was used following manufacturer's instructions.
Chromatin immunoprecipitation (ChIP) assays
Cells were cultured for 4 h in serum-free medium and stimulated with IFN␣2 or LIF for 30 min, followed by fixation with 1% formaldehyde at room temperature for 10 min. Fixation was quenched by the addition of 2 M glycine at the final concentration of 10%, then cells were washed twice with PBS plus 0.5 mM EDTA. Cells were collected and sonicated in PBS plus 0.5 mM EDTA to shear the chromatin DNA to fragments of 500-1000 bp. The supernatant was clarified by centrifugation and 1/10 of the sonicated chromatin was saved as input. The remaining chromatin solution was incubated with rabbit polyclonal anti-STAT3 (Cell Signaling Technology) and rabbit polyclonal anti-STAT3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies or normal rabbit immunoglobulin G (Santa Cruz Biotechnology) at 4°C overnight. Antibody-protein-DNA complexes were incubated with Protein A Sepharose 4 Fast Flow (Amersham), and immunoprecipitates were washed once with RIPA buffer (10 mM Tris-HCl, pH 8; 150 mM NaCl; 0.1% SDS; 1% Nonidet P-40; 0.1% sodium deoxycholate; and Complete Protease Inhibitor Cocktail), twice with RIPA-500 buffer (10 mM Tris-HCl, pH 8; 500 mM NaCl; 0.1% SDS; 1% Nonidet P-40; 0.1% sodium deoxycholate; and Complete Protease Inhibitor Cocktail), once with LiCl buffer (10 mM Tris-HCl, pH 8; 250 mM LiCl; 0.5% Nonidet P-40; 0.5% sodium deoxycholate; 1 mM EDTA; and Complete Protease Inhibitor Cocktail), and one last time with TBS buffer (20 mM Tris-HCl, pH 7.6; and 137 mM NaCl). Bound proteins were eluted from the beads in elution buffer (1% SDS and 0.1 M NaHCO 3 ) by incubation at room temperature for 30 min while shaking. Cross-linking was reverted by incubation at 65°C overnight. All samples were treated with 50 ng/l of RNase A and 100 ng/l of Proteinase K. DNA fragments were purified using the QIAquick PCR purification kit (Qiagen, Venlo, Netherlands) and subjected to quantitative PCR using SYBR Green Master (Roche Applied Science) with the specific primer set for c-FOS: 5-GCAGCCCGCGAGCAGTT-3 (forward), 5-GCCTTGGCGCGTGTCCTAATC-3 (reverse). For SOCS3, the Universal ProbeLibrary Assay (Roche Applied Science) was used with primers 5-AAAAGGGGAAGGGGAACC-3 (forward) and 5-GGAGAGCGGGCAGTTCTA-3 (reverse) in combination with probe 85. The results were analyzed using the ⌬⌬C T method. The fold change of STAT3 promoter occupancy was calculated by normalizing the relative amount to the input and comparing with untreated cells.
siRNA transfection
Renilla luciferase (RL), HDAC1, HDAC2, and HDAC3 siRNA On-Target Plus SMARTpools were purchased from Thermo Scientific (Dharmacon RNAi Technology, Lafayette, CO, USA) and transfection (siRNA final concentration 50 nM) was performed following the manufacturer's instructions. Western blot analysis to verify silencing efficiency and cytokine stimulation for the luciferase assays were performed at 72 h after transfection.
Quantitative RT-PCR (qRT-PCR)
Cell lysates were homogenized with the QiaShredder Column (Qiagen), and total cellular RNA was extracted with the RNeasy Mini kit (Qiagen) following manufacturer's instructions. Equal amounts of RNA (0.5 g) were used for reverse transcription using the Primescript RT Reagent kit (Takara Bio, Shiga, Japan), following the manufacturer's instructions. A 1:20 dilution of the cDNA products was amplified in quantitative PCR following the Universal ProbeLibrary System (Roche Applied Science) guidelines and processed in a LightCycler 480 Real-Time PCR System thermocycler (Roche Applied Science), and the results were analyzed using the ⌬⌬C T method. The primers and the probes used in the assays were selected with the online tool Universal ProbeLibrary Assay Design Center (Roche Applied Science) and were as follows: human GAPDH 5-AGCCACATCGCTCAGACAC-3 (forward), 5-GCCCAATACGACCAAATCC-3 (reverse) in combination with probe 60; human SOCS3 5-CTTCGACTGCGTGCTCAA-3 (forward), 5-GTAGGTGGCGAGGGGAAG-3 (reverse) in combination with probe 1; human c-FOS 5-CTACCACTCACCCGCAGACT-3 (forward), 5-AGGTCCGTGCAGAAGTCCT-3 (reverse) in combination with probe 67; human EGR1 5-AGCCCTACGAGCACCT-GAC-3 (forward), 5-GGTTTGGCTGGGGTAACTG-3 (reverse) in combination with probe #22, human ISG15 5-GCGAACT-CATCTTTGCCAGT-3 (forward), 5-AGCATCTTCACCGTCAG-GTC-3 (reverse) in combination with probe 76; human ISG54 5-TGGTGGCAGAAGAGGAAGAT-3 (forward), 5-GTAGGCT-GCTCTCCAAGGAA-3 (reverse) in combination with probe 27; human 2Ј5ЈOAS 5-GACGGATGTTAGCCTGCTG-3 (forward), 5-TGGGGATTTGGTTTGGTG-3 (reverse) in combination with probe 43. The fold change of mRNA expression was calculated by normalizing the relative amount to the internal control GAPDH and comparing with untreated cells or cells treated with Renilla luciferase (RL) siRNA.
Immunofluorescence analysis and confocal microscopy
Cells were seeded on coverslips and grown in serum-free medium for 16 h. Fixation, permeabilization, and staining were performed as described previously (19) . STAT3 was visualized with a 1:1600 dilution of the anti-STAT3 antibody, followed by probing with a 1:300 dilution of Alexa Fluor 488-conjugated goat anti-mouse IgG. Staining with 4,6-diamidino-2-phenylindole (DAPI) was used to stain the cell nuclei. A motorized inverted IX81 FluoView FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan) was used to record high-resolution images. 
RESULTS
Uncoupling of STAT3 phosphorylation and STAT3-responsive gene induction in type I IFN signaling
Type I IFNs were reported to induce STAT3 phosphorylation in various cell types (4) . Since phosphorylation of STAT3 on Tyr705 has been widely used as a marker for its activity as a transcription factor, we first analyzed STAT3 phosphorylation and STAT3 transcriptional activity on IFN␣2 treatment. Therefore, HEK293T cells were stimulated with increasing amounts of IFN␣2, and the total lysates were immunoblotted to detect endogenous STAT3 Tyr705 phosphorylation (Fig. 1A) . As expected, IFN␣2 stimulation strongly induced STAT3 phosphorylation, in a dose-dependent manner. Next, we compared the kinetics of STAT3 activation on treatment with IFN␣2 and LIF. LIF is a member of the IL-6 cytokine subfamily known to signal mainly through the activation of STAT3 (20) and is here used as a positive control for STAT3 activity. Figure 1B shows that not only LIF but also IFN␣2, albeit slightly weaker, could induce a marked phosphorylation of STAT3. IFN␣2 induced a strong STAT3 phosphorylation 30 min after treatment, which decreased slowly with time. Of note, LIF treatment led to a prolonged phosphorylation of STAT3, still evident 24 h after stimulation. Besides phosphorylation, the transcriptional activity of STAT3 is additionally regulated by the acetylation of multiple lysine residues (8 -9, 21) . For this reason, we analyzed the levels of STAT3 acetylation after IFN␣2 and LIF treatment. Figure 1C shows that both cytokines Total cell extracts were blotted with anti-phospho STAT3 (Tyr705) and anti-STAT3 antibody. C) Kinetics of STAT3 acetylation on IFN␣2 and LIF treatment. HEK293T cells were transfected with pMET7-Etag-hSTAT3 for 48 h, cultured for 4 h in DMEM without FCS, and then stimulated with IFN␣2 or LIF (both 10 ng/ml) for the indicated time periods. Acetylated lysines were immunoprecipitated with an anti-acetyl lysine antibody, and acetylated STAT3 was revealed with an anti-STAT3 antibody. Total lysates were collected before immunoprecipitation and blotted with anti-STAT3 antibody. D, E) Impaired STAT3 transcriptional activity on IFN␣2 treatment. HEK293T cells were transiently transfected with the pXP2d2-rPAP1-luciferase reporter alone (D) or together with the pCAGGS-HA-STAT3Y705F (E) and left nonstimulated (NS) or stimulated for 24 h with the indicated amount of IFN␣2 or LIF (or 10 ng/ml if not specified). Luciferase readout is expressed as a ratio between stimulated and unstimulated values. ***P Ͻ 0.001; t test. F-I) qRT-PCR analysis representing the relative mRNA levels of SOCS3 (F), c-FOS (G), ISG54 (H), and ISG15 (I). HEK293T cells were cultured 4 h in DMEM without FCS and then left nonstimulated or stimulated with IFN␣2 or LIF (both 10 ng/ml) for the indicated time points. Graphs represent the mRNA levels relative to the nonstimulated samples. All results are representative of 3 independent experiments. Error bars indicate sd from triplicates. ***P Ͻ 0.001; 1-way ANOVA with Bonferroni test.
induced STAT3 acetylation at comparable levels, with a peak at 30 min after stimulation. We further investigated the transcriptional activity of STAT3 in type I IFN signaling by measuring the activation of a STAT3-dependent reporter, consisting of the luciferase reporter gene under control of the rPAP1 promoter. HEK293T cells were transiently transfected with the rPAP1 reporter and stimulated with IFN␣2 or LIF. Interestingly, we found that IFN␣2 stimulation completely failed to activate the rPAP1 reporter (Fig. 1D) , in contrast to LIF treatment. To demonstrate the specificity of the rPAP1 promoter for activated STAT3, the cells were cotransfected with a dominant negative form of STAT3 (STAT3Y705F), where the tyrosine 705 is mutated to phenylalanine. Figure 1E shows that the presence of a dominant negative form of STAT3 completely abrogated the activation of the reporter. Next, we investigated whether, upon IFN␣2 treatment, phosphorylated STAT3 would induce the transcription of the endogenous genes SOCS3 and c-FOS, two known target genes of activated STAT3. HEK293T cells were stimulated for different time periods with either IFN␣2 or LIF, and transcription of SOCS3 and c-FOS genes was measured by qRT-PCR. In agreement with the reporterbased assay and again in strong contrast with LIF treatment, IFN␣2 treatment failed to induce SOCS3 and c-FOS gene transcription (Fig. 1F, G) . As expected, IFN␣2 treatment strongly induced the transcription of the ISGF3-responsive genes ISG54 and ISG15 (Fig. 1H,  I ). Taken together, these results show that IFN␣2 treatment stimulates STAT3 phosphorylation and acetylation but, surprisingly, STAT3 transcriptional activity is impaired. We conclude that STAT3 activation (through phosphorylation/acetylation) and STAT3 transcriptional activity are different processes that can be uncoupled.
IFN␣-induces STAT3 nuclear translocation and DNA binding
The inhibition of STAT3 transcriptional activity observed after IFN␣ stimulation can be due to an impaired nuclear translocation or DNA binding. To evaluate these possibilities, we prepared nuclear, cytoplasmic, and total extracts after IFN␣2 or LIF stimulation of HEK293T cells and checked for the presence of phosphorylated STAT3. As shown in Fig. 2A , both IFN␣2 and LIF stimulation led to a comparable partial accumulation of phospho-STAT3 in the nucleus. Next, the ability of STAT3 to bind DNA after IFN␣2 treatment was assayed. The nuclear extracts of IFN␣2-or LIF-stimulated cells were incubated with immobilized oligonucleotides containing a generic STAT-consensus binding site (5Ј-TTCCCGGAA-3Ј), and bound endogenous STAT3 was detected using a specific anti-STAT3 antibody. As shown in Fig. 2B , both cytokines stimulated STAT3 binding to the STAT-consensus DNA sequence. Taken together, these results indicate that the impairment of STAT3-dependent gene transcription is not due to lack of nuclear translocation or DNA-binding of the transcription factor. We next asked whether IFN␣2 stimulation would lead to the recruitment of STAT3 to the endogenous promoters of SOCS3 and c-FOS genes. HEK293T cells were stimulated with either IFN␣2 or LIF, and the occupancy of STAT3 on the promoters was investigated by ChIP assays. Figure 2C shows that IFN␣2 strongly induced the recruitment of STAT3 at the c-FOS promoter, to a similar extent as LIF treatment. IFN␣2 A) Nuclear translocation of STAT3 upon IFN␣2 and LIF treatment. HEK293T cells were cultured for 4 h in DMEM without FCS and then left nonstimulated (NS) or stimulated with IFN␣2 or LIF (both 10 ng/ml) for 20 min. Nuclear, cytoplasmic, and total cell extracts were prepared, and similar amounts of protein extracts were used for each condition, as quantified using a Bradford (Bio-Rad) assay. Extracts were then blotted, and the membranes were probed with anti-phospho-STAT3 (Tyr705) and anti-STAT3 antibodies. Anti-GAPDH and anti-LAMIN A/C antibodies were used as cytoplasmic and nuclear markers, respectively. B) IFN␣2 and LIF stimulation leads to comparable levels of STAT3-DNA complexes. Nuclear extracts from HEK293T cells prepared as described in A were assayed for the formation of STAT3-DNA complexes using the TransAm Kit (Active Motif) following the manufacturer's instructions. The results are representative of 2 independent experiments. **P Ͻ 0.01, ***P Ͻ 0.001; t test. C, D) STAT3 binds to the endogenous c-FOS and SOCS3 promoters. ChIP assays were performed to examine the occupancy of STAT3 on the c-FOS (C) and SOCS3 (D) promoters, as described in Materials and Methods. Immunoprecipitated DNA from nonstimulated or IFN␣2 or LIF stimulated (both 10 ng/ml, 30 min) HEK293T cells was subjected to qRT-PCR using primers specific for the two promoters. Graphs represent STAT3 occupancy levels relative to NS sample. Results are representative of 3 independent experiments. Error bars indicate sd from triplicates. *P Ͻ 0.05, ***P Ͻ 0.001; 1-way ANOVA with Bonferroni test. stimulation also induced the recruitment of STAT3 at the SOCS3 promoter, as shown in Fig. 2D , although to a lesser extent than LIF treatment. In summary, these data show that IFN␣2 stimulates the nuclear translocation of phospho-STAT3 and its recruitment to the STAT3-responsive promoters, c-FOS and SOCS3, without activating their transcription.
Simultaneous treatment with IFN␣ and TSA leads to the restoration of IFN-dependent STAT3 transcriptional activity
The transcriptional activity of STAT3 has been shown to be positively regulated by the acetylation of multiple lysine residues (8 -9, 22) . As a consequence, the activity of STAT3 can be downmodulated by the interaction with different HDACs (9 -11) . In this context, we asked whether deacetylation could explain the hampered transcriptional activity of STAT3. Therefore, Flp-In T-Rex HEK293 cells stably expressing the rPAP1-luciferase reporter were simultaneously stimulated with IFN␣2 and with the potent HDACs inhibitor TSA, and then compared to the samples stimulated with either IFN␣2 or TSA. Clearly, cotreatment of the cells with both TSA and IFN␣2 restored the transcriptional activity of STAT3, as shown by the activation of the rPAP1 reporter (Fig. 3A) . Of note, Fig. 3B shows that, although cotreatment with IFN␣2 and TSA restored STAT3-dependent transcription, it did not alter the phosphorylation pattern of STAT3, suggesting the presence of a regulatory mechanism acting downstream of the phosphorylation event. In agreement with the reporter assay, the combined stimulation with TSA and IFN␣2 also led to the transcription of the STAT3-stimulated c-FOS and EGR1 genes in the 2fTGH cell line (Fig. 3C, D) , further demonstrating that the activity of the HDACs is directly involved in the repression of STAT3-responsive genes on IFN␣2 treatment. Of note, in the same cell line and using the same stimuli, TSA efficiently abrogated the expression of the ISGF3-responsive genes ISG15 and ISG54 induced by IFN␣2 treatment (Fig. 3E, F) . We next assessed the dynamics of the subcellular localization of endogenous STAT3 by confocal microscopy imaging on 2fTGH cells stimu- A) Flp-In T-Rex HEK293 cells stably expressing the pXP2d2-rPAP1-luciferase reporter were cultured for 4 h in DMEM without FCS and then left nonstimulated (NS) or stimulated with IFN␣2 (10 ng/ ml), TSA (100 ng/ml) or a combination of the two. Luciferase assay was performed after 24 h. Luciferase read-out is expressed as a ratio between stimulated and unstimulated values. ***P Ͻ 0.001; t test. B) TSA treatment does not influence STAT3 Y705 phosphorylation. HEK293 cells were cultured for 4 h in DMEM without FCS and then left nonstimulated or stimulated with IFN␣2 (10 ng/ml), TSA (100 ng/ml), or a combination of the two for the indicated time periods. Total cell extracts were blotted with anti-phospho STAT3 (Tyr705) and anti-STAT3 antibody. C-F) qRT-PCR analysis representing the relative mRNA levels of the STAT3-responsive c-FOS (C) and EGR1 (D) genes and the ISGF3-responsive ISG15 (E) and ISG54 (F) genes. 2fTGH cells were cultured 4 h in DMEM without FCS, then left nonstimulated or stimulated with IFN␣2 (10 ng/ml), TSA (100 ng/ml), or a combination of the two for 24 h. Graphs represent mRNA levels relative to NS sample. Results are representative of 3 independent experiments. Error bars indicate sd from triplicates. ***P Ͻ 0.001; 1-way ANOVA with Bonferroni test. G) Accumulation of nuclear STAT3 after combined TSA and IFN␣ treatment. 2fTGH cells were starved for 16 h. Solvent, TSA (100 ng/ml), and/or IFN␣ (10 ng/ml) were added for the indicated times. Cells were fixed and stained, and the localization of STAT3 was assessed by confocal analysis. Confocal immunofluorescence of representative cell fields is shown.
MODULATION OF THE IFN RESPONSE BY HDAC1 AND HDAC2
lated with IFN␣2, TSA, or both ( Fig. 3G and Supplemental Fig. S1 ). In solvent-treated cells, STAT3 was evenly distributed over both the cytoplasm and nucleus. IFN␣2 treatment for 30 min induced an enhanced nuclear accumulation of STAT3, which then redistributed back to the cytoplasm at later time points. Of note, when cells were simultaneously treated with IFN␣2 and TSA, STAT3 showed a prolonged accumulation in the nucleus even after 4 h of stimulation, indicating that the activity of HDACs may affect the nuclear-cytoplasmic distribution of STAT3.
The activity of HDAC1 and HDAC2, but not HDAC3, contributes to the inhibition of STAT3 transcriptional activity on IFN␣ treatment
The acetylation status of STAT3 is counteracted by its association with HDAC1, HDAC2, and HDAC3 (9 -11). The NH 2 terminus of these HDACs contains a motif required for their homooligomerization. In addition, heterooligomers have been reported for HDAC1 with HDAC2 and HDAC3 (22, 23) . We asked whether these HDACs could be involved in the IFN-driven inhibition of STAT3 activity. The Flp-In T-Rex HEK293 cells stably expressing the rPAP1-luciferase reporter were first transfected with an irrelevant siRNA (Renilla luciferase siRNA) or with siRNAs targeting the HDACs and then stimulated with IFN␣2. Since functional redundancy in HDAC activity is possible, the three HDACs were silenced individually or in pair-wise combination (Fig. 4A) . Interestingly, the combined silencing of HDAC1 and HDAC2, but not HDAC3, enhanced the IFN-dependent STAT3 transcriptional activity. In agreement with this observation, the transcription of SOCS3 was also induced by IFN␣2 treatment in HEK293T on combined HDAC1/HDAC2 silencing (Fig. 4B) . Silencing efficiency was evaluated by immunoblotting of the total lysates with specific antibodies against the endogenous HDAC1, HDAC2, and HDAC3 (Fig. 4C) . Of note, the efficiency of the combined silencing of HDAC1 and HDAC2 was reproducibly inferior compared to the single silencing. This is in line with the previous observation that depletion of either HDAC1 or HDAC2 causes a compensatory up-regulation of HDAC2 and HDAC1, respectively (24) . Next, we analyzed the effect of HDAC1/HDAC2 silencing on MCF7 breast cancer cells. Interestingly, in this cell line, IFN␣2 stimulation led to the transcription of the STAT3-responsive genes SOCS3 and EGR1 (Fig. 4D, E) . Nonetheless, silencing of the two HDACs further raised the levels of their expression. In sharp contrast, interfering with HDAC1 and HDAC2 activities impaired the transcription of the ISGF3-dependent gene ISG54 (Fig. 4F) . We next asked whether a combined silencing of HDAC1 and HDAC2 would affect the subcellular localization of STAT3, as observed with TSA treatment (Fig. 3G and Supplemental Fig. S1 ). To this aim, MCF7 cells were transfected with an irrelevant (Renilla luciferase) siRNA or a combination of HDAC1 and HDAC2 siRNA. As shown in Fig. 4G and Supplemental  Fig. S2 , IFN␣2 treatment of MCF7 cells led to a transient nuclear accumulation of STAT3, peaking at 30 min. Of note, HDAC1/HDAC2 silencing led to a prolonged accumulation of STAT3 in the nucleus, even 4 h after IFN␣2 treatment, a time when STAT3 is normally redistributed back to the cytoplasm (RL siRNA panels). In summary, we show that HDACs, and, in particular, HDAC1 and HDAC2, exert opposed regulation on STAT3-and ISGF3-responsive gene transcription: their activity represses STAT3-dependent genes, while, on the other hand, they are necessary for the expression of ISGF3-dependent genes.
DISCUSSION
The activation of STAT3 upon type I IFN stimulation has been documented in a number of different cell types (4), but its role in type I IFN signaling is not fully understood. Whereas STAT3 activation generally promotes cell cycle progression, survival, and proliferation (12), type I IFN stimulation triggers cell apoptosis or growth arrest (25) . To better understand this functionally contradictive observation, we investigated the regulation of the transcriptional activity of STAT3 in the IFN␣ signaling pathway. Here, we show that, on IFN␣2 treatment, STAT3 phosphorylation, nuclear translocation, and DNA binding are strongly induced and comparable to LIF treatment (positive control for STAT3 activation). Yet, in contrast with LIF, IFN␣2 stimulation fails to activate the transcription of the STAT3-dependent genes SOCS3 and c-FOS, although STAT3 is efficiently recruited at their promoters. Comparing IFN␣2 and LIF treatment, we could not detect a significant difference in the degree of STAT3 Tyr705 phosphorylation that would explain the disparity in its transcriptional activity. Beside phosphorylation, other post-translational modifications have been reported to modulate STAT3 activity. Among these, acetylation, exerted by the histone acetyltransferases (HATs) p300 and CBP (26), appears to be a critical determinant in the regulation of STAT3 activity. STAT3 undergoes acetylation on different lysine residues in response to various cytokine stimuli. Acetylation positively regulates STAT3 transcriptional activity, although the precise effect of this modification depends on the acetylated residue. For instance, acetylation of STAT3 on K685 is necessary for dimer stability, a correct nucleocytoplasmic distribution, and DNA binding (9, 26) . IFN␣ has been reported to promote STAT3 acetylation on K685, as well as many cytokines belonging to the IL6 family, such as IL6, LIF, and OSM (9, 27) . In addition, STAT3 is acetylated at the NH 2 -terminal residues K49 and K87 on IL6 stimulation (28) . The lack of acetylation in KK49/87RR mutants impairs the transcriptional activity of STAT3, preventing its binding with p300, but does not influence its DNAbinding activity (8) . Recently, 3 additional lysines have been identified that may undergo acetylation (K679, K707, and K709), which all seem to be implicated in the regulation of STAT3 phosphorylation (21) . The growing number of observations and studies concerning STAT3 acetylation suggests that the list of target lysine residues may still be incomplete.
The reversible lysine acetylation of STAT3 is balanced by the opposite activity of HDACs. Besides their known role in basal gene silencing processes, HDACs are well reported to support a broad-spectrum of regulatory mechanisms, which extend to the regulation of the activity of several transcription factors (29) . Recently, also STAT3 has been reported to be regulated by HDAC1, HDAC2, and HDAC3, which associate with STAT3 and contribute to its negative regulation (9 -11) . Here, we show for the first time that endogenous HDAC1 and HDAC2 may prevent the activity of a transcription factor, STAT3, which had acquired all the hallmarks of an active transcription factor, such as phosphorylation, acetylation, nuclear translocation, and DNA binding. Indeed, cotreatment of the cells with IFN␣2 and the HDAC inhibitor TSA, as well as specific HDAC1 and HDAC2 siRNAmediated silencing, allows the activation of both the STAT3-dependent reporter rPAP1 and the transcription of STAT3-driven endogenous genes. In addition, we show that these two HDACs exert a redundant role in repressing IFN␣-activated STAT3, since interfering with the function of only one of the two HDACs does not restore STAT3 activity. This result is in agreement with the fact that HDAC1 and HDAC2 are highly related proteins that share 85% of sequence identity, which probably accounts for the overlapping functions of these two enzymes (30) .
Apart from STAT3, CBP was also shown to acetylate several other players of the IFN signaling pathway, such as IFNAR2 and the ISGF3-complex components STAT2 and IRF9, permitting the assembly of the ISGF3 complex and (32) (33) (34) . Treatment with the HDAC inhibitors TSA or valproic acid (VPA) impairs ISGs expression, although the exact molecular mechanisms for this inhibition remain unclear. HDAC inhibitors affect ISGF3 transcriptional activity without altering the tyrosine phosphorylation of STAT1 and STAT2 and without affecting their nuclear translocation or assembly on chromatin. TSA treatment was shown to prevent the IFN-stimulated binding of RNA polymerase II to the ISG54 promoter (34) . On the basis of these observations, it appears likely that HDAC regulation occurs downstream of ISGF3 activation and promoter assembly, but before the recruitment of polymerase II and the onset of transcription.
Our study assigns a broader role for HDACs, in particular, HDAC1 and HDAC2, in the regulation of type I IFN signaling. Indeed, our observation that HDACs actively repress the activity of STAT3, together with their previously described role in supporting ISGF3 signaling, indicates that HDAC1 and HDAC2 differentially modulate STAT activity in response to IFN␣: while they are required for the induction of ISGF3-responsive genes, they impair the transcription of STAT3-dependent genes. This leads us to hypothesize the presence of an acetylation-deacetylation switch (Fig. 5 ) that differentially regulates ISGF3-and STAT3-dependent transcription, hence modulating the specificity of the IFN␣ response. Similar to what has been observed for STAT1 and STAT2, TSA treatment also does not significantly alter the STAT3 phosphorylation status. Intriguingly, interfering with HDAC1 and HDAC2 function seems to affect in a reproducible manner the nuclear-cytoplasmic distribution dynamics of STAT3 after IFN␣2 treatment, leading to prolonged nuclear accumulation (Figs. 3G and 4G) . These results are in agreement with the recent observation that HDAC1 interacts with the NH 2 -terminal acetylation domain of STAT3 and, as such, controls its subcellular distribution (10) . Since IFN-activated STAT3 is recruited at the promoters of c-FOS and SOCS3, it seems likely that the negative regulatory mechanism exerted by HDACs on its transcriptional activity may occur downstream of DNA binding, as reported for the ISGF3 complex. Further studies will be needed to unveil the molecular mechanisms underlying the differential regulation of ISGF3 and STAT3 activity by HDAC1 and HDAC2. HDACs may act either directly on STAT molecules, modifying their acetylation pattern, or on other transcriptional cofactors, although so far, we could not detect any impairment on histone acetylation or a marked differential cofactor recruitment pattern on the c-FOS or SOCS3 promoters that could explain the absence of transcription (data not shown). Interestingly, priming experiments showed that pretreatment with IFN␣2 does not affect the LIF-induced STAT3 transcriptional activity (data not shown), suggesting the coexistence of independent mechanisms of STAT3 transcriptional activation.
Although the transcriptional activity of STAT3 is impaired, it is reasonable to assume that its activation must have an effect on the response to IFNs. For instance, activated STAT3 has been proposed to regulate STAT1-dependent signaling by sequestering it in heterodimers and thus attenuating the STAT1-dependent inflammatory response to IFN␣ (35) . In support of this hypothesis, a number of studies have confirmed that STAT1 and STAT3 reciprocally regulate each other's activities, thus contributing to maintain the specificity of cytokine signaling (36 -40) . Nevertheless, besides its function in the modulation of STAT1 signaling, STAT3 has been reported to have an active role in the IFN-driven apoptotic response in primary murine pro-B cells (41) and an antiviral response in Daudi cells (17) , underlining a cell-type dependent role for this transcription factor. Because of these cell-type specific functions, it is expected that the regulation of the transcriptional activity of STAT3 may vary in different cell types. Of note, in contrast with HEK293T and 2fTGH cells, treatment of the breast cancer cell line MCF7 with IFN␣2 led to activation of the STAT3-dependent genes SOCS3 and EGR1. Also in this context, HDAC1 and HDAC2 silencing enhanced STAT3-target gene activation, while impaired ISGF3-dependent transcription.
In conclusion, we demonstrate that HDAC1 and HDAC2 differently modulate STAT activation in response to IFN␣2, as they simultaneously behave as transcription-suppressors, i.e., in the case of STAT3, and as transcription-mediators, i.e., in the case of ISGF3, thus depending on the specific STAT-driven gene promoter context. The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferoninducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses [1] [2] [3] [4] [5] [6] [7] . Both the magnitude and breadth of the IFITM proteins' in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses. Using a knockout mouse model 8 , we now test this hypothesis directly and find that IFITM3 is essential for defending the host against influenza A virus in vivo. Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-pathogenicity influenza virus, mirroring the destruction inflicted by the highly pathogenic 1918 'Spanish' influenza 9, 10 . Similar increased viral replication is seen in vitro, with protection rescued by the re-introduction of Ifitm3. To test the role of IFITM3 in human influenza virus infection, we assessed the IFITM3 alleles of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses. We find that a statistically significant number of hospitalized subjects show enrichment for a minor IFITM3 allele (SNP rs12252-C) that alters a splice acceptor site, and functional assays show the minor CC genotype IFITM3 has reduced influenza virus restriction in vitro. Together these data reveal that the action of a single intrinsic immune effector, IFITM3, profoundly alters the course of influenza virus infection in mouse and humans.
IFITM3 was identified in a functional genomic screen as mediating resistance to influenza A virus, dengue virus and West Nile virus infection in vitro 1 . However, the role of the IFITM proteins in antiviral immunity in vivo is unknown. Therefore, we infected mice that are homozygous for a disruptive insertion in exon 1 of the Ifitm3 gene that abolishes its expression 8 (Ifitm3
) with a low-pathogenicity murine-adapted H3N2 influenza A virus (A/X-31). Low-pathogenicity strains of influenza do not normally cause extensive viral replication throughout the lungs, or cause the cytokine dysregulation and death typically seen after infection with highly pathogenic viral strains 9 , at the doses used (Fig. 1a) . However, low-pathogenicity-infected Ifitm3 2/2 mice became moribund, losing .25% of their original body weight and showing severe signs of clinical illness (rapid breathing, piloerection) 6 days after infection. In comparison, wild-type littermates shed ,20% of their original body weight, before fully recovering (Fig. 1a, b) . There was little difference in virus replication in the lungs during the first 48 h *Lists of participants and their affiliations appear at the end of the paper.
Cleveland Street, London W1T 4JF, UK. 2/2 mice at all time points, but was seen to increase in wild-type mice. c, A/X-31 viral load in the lungs of mice (n . 4) was calculated over the course of infection by plaque assay. p.f.u., plaque-forming units. Ifitm3 2/2 murine embryonic fibroblasts (n 5 3 per condition) stably expressing Ifitm3 (1), or the empty vector (2) were left untreated (blue), or incubated with IFN-a (red) or IFN-c (green), then challenged with either A/X-31 or PR/8 influenza. d, Twelve hours after infection, the cells were assessed for either haemagglutinin expression (PR/8), or nucleoprotein expression (A/X-31) IFITM3 expression was determined to be present (1) or absent (2) by western blotting (Supplementary Fig. 2) . Results show means 6 s.d. Statistical significance was assessed by Student's t-test (**P , 0.01; ***P , 0.001).
of infection. However, virus persisted and was not cleared as quickly in Ifitm3 2/2 mice, whose lungs contained tenfold higher levels of replicating virus than the wild-type mice at 6 days post-infection (Fig. 1c) . No viral RNA was detected in the heart, brain or spleen of infected wild-type or Ifitm3 2/2 mice over the course of infection, revealing that systemic viraemia was not occurring. Full-genome sequencing of virus removed from the lungs of wild-type and Ifitm3 2/2 mice showed no genetic variation. We demonstrated that IFITM3 protein expression after influenza infection was absent in Ifitm3 2/2 mice but increased substantially in wild-type controls (Fig. 1b and Supplementary Fig. 1 ). Infection of wild-type and Ifitm3 2/2 mice with a human isolate of pandemic influenza A H1N1 (pH1N1/09) resulted in the same severe pathogenicity phenotype in the Ifitm3 2/2 mice (Fig. 1a, b) . Mouse embryonic fibroblast (MEF) lines generated from multiple matched littermates demonstrated that Ifitm3 2/2 cells are infected more readily in vitro, and lack much of the protective effects of interferon (IFN). Importantly, the stable restoration of IFITM3 conferred wild-type levels of restriction against either the X-31 strain, or the more pathogenic Puerto Rico/8/34 (PR/8) influenza strain ( Fig. 1d and Supplementary Fig. 2) . In addition to the role of IFITM3 in restriction of high-pathogenicity H5N1 avian influenza 7 , we also show that it limits infection by recent human influenza A virus isolates and influenza B virus ( Supplementary Fig. 3 ). Therefore, enhanced pathogenesis to diverse influenza viruses is attributable to loss of Ifitm3 expression and consequential changes in immune defence of the lungs.
Examination of lung pathology showed fulminant viral pneumonia with substantial damage and severe inflammation in the infected Ifitm3 2/2 mice. Lung pathology was characterized by extensive oedema and red blood cell extravasation, as well as pneumonia, haemorrhagic pleural effusion and multiple, large lesions on all lung lobes (Fig. 2a, b and Supplementary Fig. 4 ). We note that this pathology is similar to that produced by infection of mice and primates with 1918 H1N1 virus [9] [10] [11] . Given the higher viral load in Ifitm3 2/2 mice and increased replication of influenza A virus in Ifitm3-deleted cells in vitro (Fig. 1d) , we examined both viral nucleic acid and protein distribution in the lung. Influenza virus infection penetrated deeper into the lung tissue in Ifitm3 2/2 compared to wild-type mice whose infection was primarily restricted to the bronchioles, with minimal alveolar infection. Influenza virus was detected throughout the entire lung in Ifitm3 2/2 sections, spreading extensively in both bronchioles and alveoli (Fig. 2c) . Histopathology showed marked infiltration of cells and debris into the bronchoalveolar space of Ifitm3 2/2 mice ( Fig. 2b  and Supplementary Fig. 4b ). The extent and mechanism of cell damage was investigated by TdT-mediated dUTP nick end labelling (TUNEL) assay, showing widespread cellular apoptosis occurring 6 days postinfection in Ifitm3 2/2 mice, whereas apoptosis in wild-type lungs was very limited (Supplementary Fig. 4c) . Together, the Ifitm3 2/2 mouse pathology is consistent with infection by high-pathogenicity strains of influenza A virus, where widespread apoptosis occurs by day 6 postinfection, whereas lungs from low-pathogenicity infections were similar to those of wild-type mice, displaying minimal damage 9, 12, 13 . Analysis of cell populations resident in the lung tissue on day 6 postinfection showed that Ifitm3 2/2 mice had significantly reduced proportions of CD4 1 (P 5 0.004) and CD8 1 T cells (P 5 0.02) and natural killer (NK) cells (P 5 0.0001), but an elevated proportion of neutrophils (P 5 0.007) (Fig. 3a) . Despite the extensive cellular infiltration (Supplementary Figs 4b, 5a) , the absolute numbers of CD4 1 T-lymphocytes in the lungs of the Ifitm3 2/2 mice were also lower and neutrophils increased compared to wild-type mice (Supplementary Fig. 6 ). The peripheral blood of infected Ifitm3 2/2 mice showed leukopenia (Supplementary Fig. 5c ). Blood differential cell counts indicated marked depletion of lymphocytes on day 2 postinfection in the Ifitm3 2/2 mice (P 5 0.04) (Fig. 3b) , reflecting changes observed previously in high-pathogenicity (but not low-pathogenicity) influenza infections in both humans and animal models 9, 12, 14, 15 . Heightened cytokine and chemokine levels are also hallmarks of severe influenza infection, having been observed in both human and animal models 9, 16 . We observed exaggerated pro-inflammatory responses in the lungs of Ifitm3 2/2 mice with levels of TNF-a, IL-6, G-CSF and MCP-1 showing the most marked increase (Fig. 3c and Supplementary  Fig. 7 ). This is indicative of the extent of viral spread within the lungs, as TNF-a and IL-6 are released from cells upon infection 17 . Consistent with the immunopathology data above, these changes are comparable in level to those seen with non-H5N1 high-pathogenicity influenza infections 9 . Neutrophil chemotaxis, together with elevated proinflammatory cytokine secretion, has previously been reported as one of the primary causes of acute lung injury 18 .
To investigate further the extensive damage observed with lowpathogenicity influenza A virus infection in the absence of IFITM3, we infected both wild-type and Ifitm3 2/2 mice with a PR/8 influenza strain deficient for the multi-functional NS1 gene (delNS1) 19, 20 . NS1 is the primary influenza virus interferon antagonist, with multiple inhibitory effects on host immune pathways 20, 21 . We found that delNS1 virus was attenuated in both wild-type and Ifitm3 2/2 mice, and whereas the isogenic PR/8 strain expressing NS1 showed typical high pathogenicity in all mice tested, lower doses of PR/8 influenza (although lethal in both genotypes of mice) caused accelerated weight loss in Ifitm3 2/2 compared to wild-type mice ( Supplementary Fig. 8 ). As delNS1 influenza A virus retains its pathogenicity in IFN-deficient mice 19 , this suggests that Ifitm3 2/2 mice can mount an adequate IFNmediated anti-viral response without extensive morbidity, and that IFITM3 blocking viral replication occurs before NS1-mediated IFN . Therefore, unchecked lung viral replication and an enhanced inflammatory response accounts for the profoundly deleterious effects of viral infection in Ifitm3 2/2 mice. The human IFITM3 gene has two exons and is predicted to encode two splice variants that differ by the presence or absence of the first amino-terminal 21 amino acids (Fig. 4a) . Currently, 13 non-synonymous, 13 synonymous, one in-frame stop and one splice site acceptor-altering single nucleotide polymorphisms (SNPs) have been reported in the translated IFITM3 sequence (Supplementary Table 1 ). Using tests sensitive to recent positive selection, we can find evidence for positive selection on the IFITM3 locus in human populations acting over the last tens of thousands of years in Africa (Fig. 4b, c) . We therefore 2/2 mice 6 days post-infection. b, Systemic lymphopenia was confirmed through differential analysis of peripheral blood cell counts, which showed a significant depletion of lymphocytes on day 2 post-infection of
Ifitm3
2/2 mice (monocytes, black; lymphocytes, grey; polymorphonuclear leukocytes, white). NK, natural killer. c, Levels of pro-inflammatory cytokines were also recorded as being elevated in Ifitm3 2/2 lungs over the course of infection (1/1, black; 2/2, white). Results show means 6 s.d., n 5 5. Statistical significance was assessed by Student's t-test (*P , 0.05, **P , 0.01, ***P , 0.001). Of these, 86.8% of patients carried majority alleles for all 28 SNPs in the coding sequence of the gene, but 13.2% possessed known variants. In particular, we discovered over-representation in cases of the synonymous SNP rs12252, wherein the majority T allele is substituted for a minority C allele, which alters the first splice acceptor site and may be associated with the IFITM3 splice variant (ENST00000526811), which encodes an IFITM3 protein lacking the first 21 amino acids due to the use of an alternative start codon.
The allele frequencies for SNP rs12252 vary in different human populations (Supplementary Table 2 ). The ancestral (C) allele, reported in chimpanzees, is rare in sub-Saharan African and European populations (derived allele frequency (DAF) 0.093 and 0.026-0.036, respectively), but more frequent in other populations (Supplementary Table 2 ). SNP rs12252 is notable for its high level of differentiation between Europeans and East Asians, although the fixation index (F ST , a measure of population differentiation) does not reach statistical significance. The genotypes associated with rs12252 in Caucasians hospitalized following influenza infection differ significantly from ethnically matched Europeans in 1000 Genomes sequence data and from genotypes imputed against the June 2011 release of the 1000 Genomes phased haplotypes from the UK, Netherlands and Germany (Wellcome Trust Case Control Consortium 1 (WTCCC1, UK): P 5 0.00006, Netherlands: P 5 0.00001, Germany: P 5 0.00007; Fisher's exact test). Patients' genotypes also depart from HardyWeinberg equilibrium (P 5 0.003), showing an excess of C alleles in this population (Fig. 4d) . Principal components analysis of over 100,000 autosomal SNPs showed no evidence of hidden population structure differences between WTCCC controls and a subset of the hospitalised individuals from this study ( Supplementary Fig. 9a, b) .
To test the functional significance of the IFITM3 rs12252 polymorphism in vitro, we confirmed the genotypes of HapMap lymphoblastoid cell lines (LCLs) homozygous for either the majority (TT) or minority (CC) variant IFITM3 alleles (Supplementary Fig. 9c ). We next challenged the LCLs with influenza A virus and found that the minority (CC) variant was more susceptible to infection, and this vulnerability correlated with lower levels of IFITM3 protein expression compared to the majority (TT) variant cells ( Supplementary Fig. 10 ). Although we did not detect the IFITM3 splice variant protein (ENST00000526811) in the CC LCLs, we nonetheless investigated the possible significance of its presence by stably expressing the N-terminally truncated (ND21) and wild-type proteins to equivalent levels in human A549 lung carcinoma cell lines before infection with influenza A virus (A/WSN/1933 (WSN/33)). We found that cells expressing the ND21 protein failed to restrict viral replication when compared to wild-type IFITM3 (Fig. 4e) , consistent with previous data showing that the amino-terminal 21 amino acids of IFITM3 are required for attenuation of vesicular stomatitis virus replication in vitro Fig. 3 ).
We show here that IFITM3 expression acts as an essential barrier to influenza A virus infection in vivo and in vitro. The fulminant viral pneumonia that occurs in the absence of IFITM3 arises because of uncontrolled virus replication in the lungs, resulting in profound morbidity. In effect, the host's loss of a single immune effector, IFITM3, transforms a mild infection into one with remarkable severity. Similarly, the enrichment of the rs12252 C-allele in those hospitalized with influenza infections, together with the decreased IFITM3 levels and the increased infection of the CC-allele cells in vitro, suggests that IFITM3 also plays a pivotal role in defence against human influenza virus infections. This innate resistance factor is all the more important during encounters with a novel pandemic virus, when the host's acquired immune defences are less effective. Indeed, IFITM3-compromised individuals, and in turn populations with a higher percentage of such individuals, may be more vulnerable to the initial establishment and spread of a virus against which they lack adaptive immunity. In light of its ability to curtail the replication of a broad range of pathogenic viruses in vitro, these in vivo results suggest that IFITM3 may also shape the clinical course of additional viral infections in favour of the host, and may have done so over human evolutionary history. 20 (H1N1) in 50 ml of sterile PBS. Mouse weight was recorded daily as well as monitoring for signs of illness. Mice exceeding 25% total weight loss were killed in accordance with UK Home Office guidelines. Infected lungs were collected on days 1-6 post-infection and quantified for viral load by plaque assay and RT-qPCR with primers to influenza matrix 1 protein.
METHODS SUMMARY
Pathology of infected Ifitm3
2/2 mice. 5-mm sections of paraffin-embedded tissue were stained with haematoxylin and eosin and microscopically examined. Apoptosis was assessed by TUNEL using the TACS XL DAB In Situ Apoptosis Detection Kit (R&D Systems). Viral RNA was visualized by QuantiGene viewRNA kit (Affymetrix), with a viewRNA probe set designed to the negative stranded vRNA encoding the NP gene of A/X-31 (Affymetrix). Lung tissue was embedded in glycol methacrylate (GMA) and viral antigens stained using M149 polyclonal antibody to influenza A, B (Takara). Single cell suspensions from the lung were characterized by flow cytometry for T-lymphocytes CD4
1 or CD8 Sequencing and genetics of human IFITM3. The 1.8 kb of human IFITM3 was amplified and sequenced to identify single nucleotide polymorphisms (SNPs). SNP rs12252 was identified and compared to allele and genotype frequencies from 1000 Genomes sequencing data from different populations including 1000 Genomes imputed. SNP rs12252 allele frequencies were determined in the publicly available genotype data sets of WTCCC1 (n 5 2,938) and previously published data sets genotyped from the Netherlands (n 5 8,892) and Germany (n 5 6,253) 22 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
Intensive Care Unit, Borders General Hospital, Melrose TD6 9BS, UK. 20 Intensive Care Unit, Crosshouse Hospital, Kilmarnock KA2 0BE, UK. 21 Intensive Care Unit, Dumfries and Galloway Royal Infirmary, Dumfries DG1 4AP, UK. 22 Intensive Care Unit, Glasgow Royal Infirmary, Glasgow G4 0SF, UK. 23 Intensive Care Unit, Hairmyres Hospital, Lanarkshire G75 8RG, UK. 24 Intensive Care Unit, Inverclyde Royal Hospital, Greenock PA16 0XN, UK. 25 Intensive Care Unit, Monklands Hospital, Airdrie ML6 0JS, UK. 26 Intensive Care Unit, Ninewells Hospital, Dundee DD1 9SY, UK. 27 Intensive Care Unit, Queen Margaret Hospital, Dunfermline KY12 0SU, UK. 28 Intensive Care Unit, Raigmore Hospital, Inverness IV2 3UJ, UK. 29 Intensive Care Unit, Royal Alexandra Hospital, Paisley PA2 9PN, UK. 30 Intensive Care Unit, Southern General Hospital, Glasgow G51 4TF, UK. 31 Intensive Care Unit, St John's Hospital, Livingston EH54 6PP, UK. 32 Intensive Care Unit, Stirling Royal Infirmary, Stirling FK8 2AU, UK. 33 Intensive Care Unit, Stobhill Hospital, Glasgow G21 3UW, UK. 34 Intensive Care Unit, Victoria Hospital, Glasgow G42 9TY, UK. 35 Intensive Care Unit, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK. 36 Intensive Care Unit, Western Infirmary, Glasgow G11 6NT, UK. Patients with significant risk factors for severe disease and patients whose daily activity was limited by co-morbid illness were excluded. 53 patients, 29 male and 24 female, average age 37 (range 2-62) were selected. 46 (88%) had no concurrent co-morbidities. The remaining 6 had the following comorbid conditions: hypertension (3 patients), alcohol dependency and cerebrovascular disease (1 patient), bipolar disorder (1 patient) and kyphoscoliosis (1 patient). Four patients were pregnant. Where assessed, 36 patients had normal body mass (69%), one had a body mass index ,18.5 and 10 had a body mass index between 25 and 39.9 and one a body mass index .40. Seasonal influenza A H3N2, influenza B and pandemic influenza A pH1N1/09 were confirmed locally by viral PCR or serological tests according to regional protocols. Consistent with the prevalent influenza viruses circulating in the UK between 2009 and 2011 (ref. 29 ) 44 (85%) had pH1N1/09, 2 had pH1N1/09 and influenza B co-infection, 4 had influenza B and 2 had nonsubtyped influenza A virus infection. Of the adults, 24 required admission to an intensive care unit (ICU) and 1 required admission to a high dependency unit (HDU). The remainder were managed on medical wards and survived their illnesses. The GenISIS study was approved by the Scotland 'A' Research Ethics Committee (09/MRE00/77) and the MOSAIC study was approved by the NHS National Research Ethics Service, Outer West London REC (09/H0709/52, 09/ MRE00/67).
Consent was obtained directly from competent patients, and from relatives/ friends/welfare attorneys of incapacitated patients. Anonymized 9-ml EDTA blood samples were transported at ambient temperature. DNA was extracted using a Nucleon Kit (GenProbe) with the BACC3 protocol. DNA samples were resuspended in 1 ml TE buffer pH 7.5 (10 mM Tris-Cl pH 7.5, 1 mM EDTA pH 8.0). Sequencing and genetics. Human IFITM3 sequences were amplified from DNA obtained from peripheral blood by nested PCR (GenBank accession numbers JQ610570 to JQ610621). The first round used primers forward: 59-TGAGGGT TATGGGAGACGGGGT-39and reverse: 59-TGCTCACGGCAGGAGGCC-39, followed by an additional round using primers forward: 59-GCTTTGGGGGA ACGGTTGTG-39and reverse: 59-TGCTCACGGCAGGAGGCCCGA-39. The 1.8-kb IFITM3 band was gel-extracted and purified using the QIAquick Gel Extraction Kit (Qiagen). IFITM3 was Sanger-sequenced on an Applied Biosystems 3730xl DNA Analyzer (GATC Biotech) using a combination of eight sequencing primers (Supplementary Table 4 ). Single-nucleotide polymorphisms were identified by assembly to the human IFITM3 encoding reference sequence (accession number NC_000011.9) using Lasergene (DNAStar). Homozygotes were called based on high, single base peaks with high Phred quality scores, whereas heterozygotes were identified based on low, overlapping peaks of two bases with lower Phred quality scores relative to surrounding base calls (Supplementary Fig. 9 ). We identified SNP rs12252 in our sequencing and compared the allele and genotype frequencies to allele and genotype frequencies from 1000 Genomes sequencing data from different populations (Supplementary Table 3 ). In addition, we used the most recent release of phased 1000 Genomes data 30 to impute the region surrounding SNP rs12252 to determine allele frequencies in the publicly available genotype data set of WTCCC1 controls (n 5 2,938) and four previously published data sets genotyped from the Netherlands (n 5 8,892) and Germany (n 5 6,253) 22 . In the imputation, samples genotyped with Illumina 550k, 610k and 670k platforms were imputed against the June 2011 release of 1000 Genotypes phased haplotypes using the Impute software We assessed for population stratification by principal component analysis. Genotype data from the WTCCC1 1958 Birth Cohort data set were obtained from the European Genotype Archive with permission, reformatted and merged with genotype data from the GenISIS study to match 113,819 SNPs present in both cohorts. Suspected strand mismatches were removed by identifying SNPs with more than 2 genotypes and using the LD method as implemented in Plink (v1.07) 32 , resulting in 105,362 matched SNPs. Quality control was applied in GenABEL version 1.6-9 to genotype data for these SNPs for the GenISIS cases and 1,499 individuals from WTCCC. Thresholds for quality control (deviation from Hardy-Weinberg equilibrium (P , 0.05), minor allele frequency (MAF) , 0.0005, call rate ,98% in all samples) were applied iteratively to identify all markers and subjects passing all quality control criteria, followed by principal component analysis using GenABEL. We tested for positive selection using both a haplotype-based test (jXP-EHH-maxj) and allele frequency spectrum-based test statistics, namely the CLR 23-25 on 10-kb windows across the entire genome as described previously 30, 33 . The three statistics were combined and the combined P value was plotted corresponding to the 10-kb windows.
